◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › AZN

AstraZeneca PLC (AZN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-07-19

AstraZeneca PLC (AZN) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Cambridge, United Kingdom with about 96,100 employees. Its market capitalization is roughly $263 billion. In the fiscal year ended 2025-12-31, AZN reported $58.7B in revenue and $10.3B in net income.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Interactive charts & full statements → Open the AZN valuation workbench →

AZN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$60.4B	$58.7B	$54.1B	$45.8B	$44.4B	$37.4B	$26.6B	$24.4B	$22.1B	$22.5B	$23.0B	$24.7B	$26.5B	$25.8B	$28.0B	$33.6B	$33.3B	$32.8B	$31.6B	$29.6B	$26.5B
Gross Profit	$49.4B	$48.1B	$43.9B	$37.5B	$32.0B	$25.0B	$21.3B	$19.5B	$17.2B	$18.1B	$18.9B	$20.1B	$20.7B	$20.5B	$22.6B	$27.6B	$26.9B	$27.0B	$25.0B	$23.1B	$20.9B
Gross Margin %	81.7%	81.9%	81.1%	82.0%	72.1%	66.8%	80.1%	79.8%	77.7%	80.8%	82.1%	81.2%	78.0%	79.6%	80.7%	82.1%	80.8%	82.4%	79.1%	78.3%	79.0%
Operating Income (EBIT)	$14.3B	$13.7B	$10.0B	$8.2B	$3.8B	$1.1B	$5.2B	$2.9B	$3.4B	$3.7B	$4.9B	$4.1B	$2.1B	$3.7B	$8.1B	$12.8B	$11.5B	$11.5B	$9.1B	$8.1B	$8.2B
Operating Margin %	23.7%	23.4%	18.5%	17.9%	8.5%	2.8%	19.4%	12.0%	15.3%	16.4%	21.3%	16.7%	8.1%	14.4%	29.1%	38.1%	34.5%	35.2%	28.9%	27.4%	31.0%
Net Income	$10.4B	$10.3B	$7.0B	$6.0B	$3.3B	$112M	$3.2B	$1.3B	$2.2B	$3.0B	$3.5B	$2.8B	$1.2B	$2.6B	$6.2B	$9.9B	$8.1B	$7.5B	$6.1B	$5.6B	$6.0B
Net Margin %	17.2%	17.5%	13.0%	13.0%	7.4%	0.3%	12.0%	5.5%	9.8%	13.4%	15.2%	11.4%	4.6%	9.9%	22.3%	29.5%	24.2%	22.9%	19.3%	18.9%	22.8%
EBITDA	$20.5B	$19.8B	$15.4B	$13.4B	$9.1B	$5.1B	$8.1B	$6.7B	$7.1B	$6.6B	$7.3B	$7.0B	$5.5B	$8.3B	$10.7B	$15.4B	$14.7B	$13.9B	$12.6B	$9.9B	$9.6B
Earnings Per Share (EPS)	$6.66	$6.57	$4.50	$3.81	$2.11	$0.16	$4.87	$2.05	$3.40	$4.74	$5.53	$4.47	$1.95	$4.08	$9.87	$14.51	$11.14	$10.37	$8.40	$7.47	$7.70
Shares Outstanding (M)	1,561M	1,562M	1,563M	1,562M	1,560M	714M	656M	650M	634M	634M	633M	632M	632M	627M	632M	684M	723M	725M	726M	749M	785M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$15.3B	$15.5B	$15.2B	$14.5B	$13.6B	$14.9B	$13.6B	$12.9B
Gross Profit	$12.6B	$12.4B	$12.4B	$12.0B	$11.3B	$12.2B	$10.5B	$10.8B
Gross Margin %	82.5%	79.9%	81.6%	82.9%	83.5%	81.7%	77.3%	83.1%
Operating Income (EBIT)	$4.2B	$3.0B	$3.6B	$3.5B	$3.7B	$2.0B	$2.1B	$2.7B
Operating Margin %	27.8%	19.2%	23.6%	24.3%	27.0%	13.7%	15.5%	21.2%
Net Income	$3.1B	$2.3B	$2.5B	$2.5B	$2.9B	$1.5B	$1.4B	$1.9B
Net Margin %	20.2%	15.0%	16.7%	17.0%	21.5%	10.1%	10.5%	14.9%
EBITDA	$5.7B	$4.6B	$5.2B	$5.0B	$5.0B	$2.8B	$4.1B	$4.1B
Earnings Per Share (EPS)	$1.97	$1.49	$1.62	$1.57	$3.74	$1.92	$1.83	$2.47
Shares Outstanding (M)	1,561M	1,562M	1,561M	1,559M	780M	781M	780M	780M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$14.3B	$14.6B	$11.9B	$10.3B	$9.8B	$6.0B	$4.8B	$3.0B	$2.6B	$3.6B	$4.1B	$3.3B	$7.1B	$7.4B	$6.9B	$7.8B	$10.7B	$11.7B	$8.7B	$7.5B	$7.7B
Capital Expenditures (CapEx)	$6.2B	$5.9B	$4.6B	$3.8B	$2.6B	$2.2B	$2.6B	$2.5B	$1.4B	$1.6B	$2.3B	$2.8B	$2.8B	$2.1B	$4.6B	$1.3B	$2.4B	$3.0B	$4.0B	$1.7B	$1.3B
Free Cash Flow (FCF)	$8.1B	$8.7B	$7.3B	$6.6B	$7.2B	$3.8B	$2.2B	$509M	$1.2B	$2.0B	$1.8B	$536M	$4.3B	$5.3B	$2.3B	$6.5B	$8.3B	$8.8B	$4.7B	$5.8B	$6.4B
FCF Margin %	13.4%	14.8%	13.5%	14.3%	16.3%	10.1%	8.2%	2.1%	5.7%	8.7%	8.0%	2.2%	16.2%	20.7%	8.3%	19.4%	24.8%	26.8%	14.9%	19.7%	24.0%
Dividends Paid	$4.9B	$5.0B	$4.6B	$4.5B	$4.4B	$3.9B	$3.6B	$3.6B	$3.5B	$3.5B	$3.6B	$3.5B	$3.5B	$3.5B	$3.7B	$3.8B	$3.4B	$3.0B	$2.7B	$2.6B	$2.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$3.4B	$2.4B	$5.1B	$3.4B	$3.7B	$2.9B	$3.4B	$3.1B
Capital Expenditures (CapEx)	$1.5B	$1.1B	$1.7B	$1.9B	$969M	$955M	$1.4B	$668M
Free Cash Flow (FCF)	$1.8B	$1.4B	$3.4B	$1.5B	$2.7B	$2.0B	$2.0B	$2.4B
FCF Margin %	11.9%	8.9%	22.4%	10.1%	20.2%	13.1%	14.9%	18.7%
Dividends Paid	$3.3B	$12M	$1.6B	$10M	$3.3B	$3M	$1.6B	$17M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$114.0B	$114.1B	$104.0B	$101.1B	$96.5B	$105.4B	$66.7B	$61.4B	$60.7B	$63.4B	$62.5B	$60.1B	$58.6B	$55.9B	$53.5B	$52.8B	$56.1B	$54.9B	$47.0B	$48.0B	$29.9B
Cash & Cash Equivalents	$7.6B	$5.7B	$5.5B	$5.8B	$6.2B	$6.3B	$7.8B	$5.4B	$4.8B	$3.3B	$5.0B	$6.2B	$6.4B	$9.2B	$7.7B	$7.6B	$11.1B	$9.9B	$4.3B	$5.9B	$7.1B
Total Liabilities	$66.6B	$65.4B	$63.2B	$62.0B	$59.4B	$66.1B	$51.1B	$46.8B	$46.6B	$46.7B	$45.9B	$41.6B	$38.9B	$32.6B	$29.6B	$29.4B	$32.7B	$34.1B	$30.9B	$33.0B	$14.5B
Total Debt (Short + Long-Term)	$32.4B	$28.3B	$29.0B	$27.8B	$28.4B	$29.9B	$2.4B	$2.0B	$1.8B	$2.3B	$2.3B	$925M	$2.5B	$1.8B	$901M	$2.0B	$125M	$1.9B	$993M	$4.3B	$136M
Total Shareholders' Equity	$47.3B	$48.7B	$40.8B	$39.1B	$37.0B	$39.3B	$15.6B	$13.1B	$12.5B	$15.0B	$14.9B	$18.5B	$19.6B	$23.2B	$23.7B	$23.2B	$23.2B	$20.7B	$15.9B	$14.8B	$15.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AZN viewer.

Other Companies in DRUG MANUFACTURERS - GENERAL

NVS · Novartis AG ADR — $295 billion
NVO · Novo Nordisk A/S — $216 billion

← AZI All stocks AZO →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.